INS and Hypoglycemia: In a retrospective study, treatment of obese people with T1D (average HbA1c 7.6%, BMI 33.5 kg/m2) with weekly GLP-1RA semaglutide for a year decreased HbA1c, BMI, and glucose variability (SD and coefficient of variation with continuous glucose monitoring) by 0.66%, 7,9%, and 2.5%, respectively, with no change in daily insulin dose; no episodes of severe ketoacidosis or hypoglycemia were reported (383).